Literature DB >> 8527411

Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells.

J P Zou1, N Yamamoto, T Fujii, H Takenaka, M Kobayashi, S H Herrmann, S F Wolf, H Fujiwara, T Hamaoka.   

Abstract

Unfractionated spleen cells taken from tumor-bearing mice 2 weeks after tumor implantation contained tumor-primed T cells which produced cytokines including IL-2 and IFN-gamma when cultured in vitro. With progressive tumor growth this initial lymphokine-producing capacity decreased. Here, we investigated the ability of IL-12 to (i) restore suppressed IFN-gamma production, (ii) cause tumor regression and (ii) induce anti-tumor protective immunity. Addition of rIL-12 to spleen cell cultures from 4- to 10-week-old tumor-bearing mice resulted in a striking enhancement in the production of IFN-gamma compared with cultures of these cells in the absence of rIL-12 or of normal spleen cells in the presence of rIL-12. Five i.p. injections of rIL-12 into mice bearing s.c. tumors induced complete tumor regression. This was found when rIL-12 was given at early (1-2 weeks), intermediate (4-5 weeks) or even late (7 weeks) stages of tumor growth. Furthermore, IL-12-treated mice which rejected the primary tumor exhibited complete resistance to a rechallenge with the same tumor but did not reject a second syngenetic tumor. Immunohistochemical analyses following IL-12 treatment revealed that CD4+ and CD8+ T cells infiltrate the tumor. More importantly, IFN-gamma mRNA expression was observed in fresh tumor masses from tumor-bearing mice receiving IL-12 treatment. The importance of IFN-gamma was further demonstrated by the observation that the systemic administration of anti-IFN-gamma mAb prior to IL-12 treatment completely abrogated the anti-tumor effect of IL-12. Thus, these results indicate that administration of modest levels of rIL-12 to tumor-bearing mice results in tumor regression through mechanisms involving reversal of suppressed IFN-gamma production by anti-tumor T cells and the establishment of a tumor-specific protective immune response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527411     DOI: 10.1093/intimm/7.7.1135

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  36 in total

1.  Proanthocyanidins inhibit UV-induced immunosuppression through IL-12-dependent stimulation of CD8+ effector T cells and inactivation of CD4+ T cells.

Authors:  Mudit Vaid; Tripti Singh; Anna Li; Nandan Katiyar; Samriti Sharma; Craig A Elmets; Hui Xu; Santosh K Katiyar
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-12

2.  Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma.

Authors:  S Koyama
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma.

Authors:  Michael J Robertson; Hua-Chen Chang; David Pelloso; Mark H Kaplan
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

Review 4.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Authors:  Adam J Bograd; Kei Suzuki; Eva Vertes; Christos Colovos; Eduardo A Morales; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Immunol Immunother       Date:  2011-09-13       Impact factor: 6.968

Review 5.  Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state.

Authors:  H Fujiwara; T Hamaoka
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

6.  Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine interleukin 12.

Authors:  D Popovic; K M El-Shami; E Vadai; M Feldman; E Tzehoval; L Eisenbach
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

Review 7.  Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines.

Authors:  J Dutcher; M B Atkins; K Margolin; G Weiss; J Clark; J Sosman; T Logan; F Aronson; J Mier
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

Review 8.  The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases.

Authors:  Christoph Hölscher
Journal:  Med Microbiol Immunol       Date:  2003-06-27       Impact factor: 3.402

9.  Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.

Authors:  Rosalba Salcedo; Julie A Hixon; Jimmy K Stauffer; Rashmi Jalah; Alan D Brooks; Tahira Khan; Ren-Ming Dai; Loretta Scheetz; Erin Lincoln; Timothy C Back; Douglas Powell; Arthur A Hurwitz; Thomas J Sayers; Robert Kastelein; George N Pavlakis; Barbara K Felber; Giorgio Trinchieri; Jon M Wigginton
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

10.  The clinical significance of massive intratumoral lymphocytosis in squamous cell carcinoma of the anus.

Authors:  Carlos A Rubio; Per J Nilsson; Fredrik Petersson; Ander Höög; Harald Blegen; Runjan Chetty
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.